Last reviewed · How we verify

Transfusion reaction due to serum protein reaction — Treatment Landscape & Competitive Intelligence

Transfusion reaction due to serum protein reaction (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Transfusion reaction due to serum protein reaction, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Depo-Medrol METHYLPREDNISOLONE ACETATE Pfizer Corticosteroid Glucocorticoid receptor 1959-01-01
Decadron dexamethasone Generic (originally Merck) Corticosteroid [EPC] Annexin A1, Interleukin-4, Androgen receptor 1958-10-30
Medrol methylprednisolone Generic (originally Upjohn/Pfizer) Glucocorticoid (corticosteroid) Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor 1957-10-01
Deltasone prednisone Generic (originally Schering) Corticosteroid [EPC] Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor 1955-01-01
Prelone prednisolone Generic (originally Schering) Glucocorticoid (corticosteroid) Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1 1955-01-01
Solu-Cortef hydrocortisone succinate Pfizer Corticosteroid Glucocorticoid receptor 1955-01-01
Cortef hydrocortisone Generic (originally Merck/Upjohn) Corticosteroid [EPC] Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible 1952-01-01
Cortifoam HYDROCORTISONE ACETATE Pfizer Corticosteroid Corticosteroid-binding globulin 1951-01-01
prednison prednison Wen Zhang Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor
Cortisol Cortisol University of Zurich Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 4 drugs in Transfusion reaction due to serum protein reaction
  2. Pfizer · 3 drugs in Transfusion reaction due to serum protein reaction
  3. Generic (originally Schering) · 2 drugs in Transfusion reaction due to serum protein reaction
  4. Generic (originally Upjohn/Pfizer) · 1 drug in Transfusion reaction due to serum protein reaction
  5. Hannover Medical School · 1 drug in Transfusion reaction due to serum protein reaction
  6. Leiden University Medical Center · 1 drug in Transfusion reaction due to serum protein reaction
  7. University of Zurich · 1 drug in Transfusion reaction due to serum protein reaction
  8. Wen Zhang · 1 drug in Transfusion reaction due to serum protein reaction
  9. Generic (originally Merck) · 1 drug in Transfusion reaction due to serum protein reaction
  10. Generic (originally Merck/Upjohn) · 1 drug in Transfusion reaction due to serum protein reaction

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Transfusion reaction due to serum protein reaction:

Cite this brief

Drug Landscape (2026). Transfusion reaction due to serum protein reaction — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/transfusion-reaction-due-to-serum-protein-reaction. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing